Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0SC2J
|
||||
| Former ID |
DCL000242
|
||||
| Drug Name |
Tanespimycin
|
||||
| Synonyms |
CNF-101; CP-127374; Tanespimycin (USAN); [(3S,5S,6R,7S,8E,10R,11S,12E,14E)-6-Hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-21-(prop-2-enylamino)-17-azabicyclo[16.3.1]docosa-8,12,14,18,21-pentaen-10-yl] carbamate; [(3R,5S,6R,7S,8E,10S,11S,12Z,14E)-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-21-(prop-2-enylamino)-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; 17-(Allylamino)-17-demethoxygeldanamycin; 17-AAG; 17-AG; 17-Allylaminogeldanamycin; 17AAG, Tanespimycin, Geldanamycin, NSC330507, 17-(Allylamino)-17-demethoxygeldanamycin, CP 127374
|
||||
| Drug Type |
Small molecular drug
|
||||
| Therapeutic Class |
Anticancer Agents
|
||||
| Company |
Bristol-Myers Squibb; Infinity Pharmaceuticals
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C31H43N3O8
|
||||
| InChI |
InChI=1S/C31H43N3O8/c1-8-12-33-26-21-13-17(2)14-25(41-7)27(36)19(4)15-20(5)29(42-31(32)39)24(40-6)11-9-10-18(3)30(38)34-22(28(21)37)16-23(26)35/h8-11,15-17,19,24-25,27,29,33,36H,1,12-14H2,2-7H3,(H2,32,39)(H,34,38)/b11-9+,18-10+,20-15+/t17-,19+,24+,25+,27-,29+/m1/s1
|
||||
| InChIKey |
AYUNIORJHRXIBJ-HTLBVUBBSA-N
|
||||
| CAS Number |
CAS 75747-14-7
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Heat shock protein HSP 90 | Target Info | Inhibitor | [536786], [536886], [537107], [537374] | |
| NetPath Pathway | IL2 Signaling Pathway | ||||
| TCR Signaling Pathway | |||||
| Pathway Interaction Database | Signaling events mediated by HDAC Class II | ||||
| Validated targets of C-MYC transcriptional activation | |||||
| Integrin-linked kinase signaling | |||||
| LKB1 signaling events | |||||
| Regulation of Telomerase | |||||
| Glucocorticoid receptor regulatory network | |||||
| Class I PI3K signaling events | |||||
| IL2 signaling events mediated by PI3K | |||||
| Regulation of Androgen receptor activity | |||||
| Integrins in angiogenesis | |||||
| Hypoxic and oxygen homeostasis regulation of HIF-1-alpha | |||||
| ErbB receptor signaling network | |||||
| VEGFR1 specific signals | |||||
| Signaling events mediated by VEGFR1 and VEGFR2 | |||||
| Class I PI3K signaling events mediated by Akt | |||||
| Reactome | Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | ||||
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | |||||
| Regulation of actin dynamics for phagocytic cup formation | |||||
| eNOS activation | |||||
| Regulation of PLK1 Activity at G2/M Transition | |||||
| Attenuation phase | |||||
| HSF1-dependent transactivation | |||||
| Loss of Nlp from mitotic centrosomes | |||||
| Recruitment of mitotic centrosome proteins and complexes | |||||
| Loss of proteins required for interphase microtubule organization?from the centrosome | |||||
| EPHA-mediated growth cone collapse | |||||
| VEGFA-VEGFR2 Pathway | |||||
| VEGFR2 mediated vascular permeability | |||||
| Anchoring of the basal body to the plasma membrane | |||||
| Constitutive Signaling by EGFRvIII | |||||
| WikiPathways | NRF2 pathway | ||||
| Nuclear Receptors Meta-Pathway | |||||
| Aryl Hydrocarbon Receptor Pathway | |||||
| Binding and Uptake of Ligands by Scavenger Receptors | |||||
| Signaling by ERBB2 | |||||
| Fcgamma receptor (FCGR) dependent phagocytosis | |||||
| Influenza Life Cycle | |||||
| EBV LMP1 signaling | |||||
| Aryl Hydrocarbon Receptor | |||||
| Corticotropin-releasing hormone | |||||
| TNF alpha Signaling Pathway | |||||
| Arylhydrocarbon receptor (AhR) signaling pathway | |||||
| Signaling by EGFR | |||||
| Semaphorin interactions | |||||
| Mitotic G2-G2/M phases | |||||
| Metabolism of nitric oxide | |||||
| NOD pathway | |||||
| References | |||||
| Ref 537114 | Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. | ||||
| Ref 542715 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7751). | ||||
| Ref 536786 | Targeting Hsp90: small-molecule inhibitors and their clinical development. Curr Opin Pharmacol. 2008 Aug;8(4):370-4. Epub 2008 Jul 31. | ||||
| Ref 536886 | Recent advances in Hsp90 inhibitors as antitumor agents. Anticancer Agents Med Chem. 2008 Oct;8(7):761-82. | ||||
| Ref 537107 | Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells. Cancer Res. 2009 Mar 1;69(5):1966-75. Epub 2009 Feb 24. | ||||
| Ref 537374 | Tanespimycin: the opportunities and challenges of targeting heat shock protein 90. Expert Opin Investig Drugs. 2009 Jun;18(6):861-8. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.